A P O E  ε4 influences the manifestation of Alzheimer’s disease in adults with Down’s syndrome

SHOUMITRO DEB, JOHN BRAGANZA, NADINE NORTON, HYWEL WILLIAMS, PATRICK G. KEHOE, JULIE WILLIAMS and MICHAEL J. OWEN

Background Recent studies of the relationship between the apolipoprotein E (APOE) gene and Alzheimer’s disease in adults with Down’s syndrome have revealed inconsistent results.

Aims To assess the role of the APOE gene in the manifestation of Alzheimer’s disease in adults with Down’s syndrome.

Method We studied the APOE genotypes of 24 adults with dementia and 33 non-demented adults with Down’s syndrome over 35 years of age, and an additional group of 164 non-learning disabled adults. We also carried out a meta-analysis of all previously published studies of association between APOE and Down’s syndrome, incorporating the current data.

Results We observed a non-significant excess of APOE ε4 and a reduction of ε2 in adults with dementia compared with non-demented adults with Down’s syndrome in our sample. However, meta-analysis showed a significantly higher frequency of ε4 in adults with dementia compared with non-demented adults with Down’s syndrome (odds ratio = 2.02, 95% CI 1.33–3.07, P = 0.001), but no significant reduction in the frequency of ε2.

Conclusions The APOE ε4 allele acts as a risk factor for the age-specific manifestation of Alzheimer’s disease in people with Down’s syndrome.

Declaration of interest This study was partly funded by the Medical Research Council (grant no. 9810900).

Autopsy studies have shown that adults with Down’s syndrome aged 40 years and above almost universally exhibit Alzheimer’s disease neuropathology (Mann, 1988), a fact that is supported by neuroimaging studies (Deb et al., 1992). Saunders et al. (1993) reported an association between APOE ε4 and late-onset Alzheimer’s disease. A number of studies have produced inconsistent support for APOE ε4 as a risk factor and APOE ε2 as a protective factor against Alzheimer’s disease in people with Down’s syndrome (Prasher et al., 1997; Tyrell et al., 1998). Our study examined whether the age-specific manifestation of Alzheimer’s disease in adults with Down’s syndrome was influenced by risk factors such as age, APOE status, and genotype for an intronic polymorphism in the PS-1 gene, which is also reputedly associated with late onset Alzheimer’s disease (Kehoe et al., 1996). We examined the APOE polymorphism in three groups: (a) a population-based sample of adults with dementia with Down’s syndrome aged 35 years and over; (b) an elderly group of non-demented adults with Down’s syndrome drawn from the same population-based sample; and (c) a group of normal non-demented adults selected for intelligence, collected from the same geographical area as the first two groups. We also carried out a meta-analysis comprising all published studies of association between the APOE gene and Alzheimer’s disease in adults with Down’s syndrome, incorporating the data from the current study.

METHOD

Subjects

The names of all known adults with Down’s syndrome over the age of 35 years were collected from the clinicians and staff of Community Learning Disability Teams in all five Health Districts in South Wales. Subjects were assessed for Alzheimer’s disease using the ICD–10 (World Health Organization, 1992) criteria in accordance with the guidelines produced by an international consensus panel established under the auspices of the Ageing Special Interest Group of the International Association for the Scientific Study of Intellectual Disabilities (IASSID) (Aylward et al., 1997). The diagnosis of dementia was further supported by using two observer-rated questionnaires, namely the Dementia Questionnaire for Mentally Retarded Persons (DMR) (Evenhuis, 1992) and the Dementia Scale for Down’s syndrome (DSDS) (Gedye, 1995). Both questionnaires are reported to have good inter-rater reliability and internal validity (Evenhuis, 1992; Gedye, 1995). Deb & Braganza (1999) have recently reported a positive correlation between diagnosis of dementia by a clinician in adults with Down’s syndrome and diagnosis carried out according to the DSDS criteria (specificity = 0.89, sensitivity = 0.85), and the DMR criteria (specificity = 0.92, sensitivity = 0.92).

The age of onset of dementia was determined by asking the carers of adults with Down’s syndrome when clinical symptoms of dementia were first noticed. Diagnosis of Down’s syndrome was based on the characteristic clinical features and no karyotyping was carried out. The level of intellectual disability was determined either on the basis of IQ scores or the assessment of adaptive behaviours.

We excluded adults with Down’s syndrome who showed medical, psychiatric, neurological or laboratory characteristics not related to Alzheimer’s disease, but which might explain their mental deterioration, in particular severe hearing loss, untreated hypothyroidism and depression (n = 2). In all, 24 adults with Down’s syndrome who had a diagnosis of Alzheimer’s disease were included in this study. We ascertained a second group of 33 individuals, identified as the oldest adults from a list of non-demented adults with Down’s syndrome. As the prevalence of dementia in adults with Down’s syndrome tends to increase with age (Lai & Williams, 1989), it is anticipated that those who have lived longer without manifesting clinical dementia have least risk factors for developing dementia, and therefore provides an appropriate group for comparison. Finally, a control group of 164 non-demented adults representative of the local population and unselected for intelligence were used (54%...
male, mean age 38.27 years, s.d.=12.16 years).

Genotyping
Both the adults with dementia and the non-demented adults with Down’s syndrome, and the non-demented, non-learning disabled control group were genotyped for both the APOE and PS-1 polymorphisms using standard techniques (Wenham et al., 1991; Wragg et al., 1996). For a detailed description of PS-1 data see Deb et al. (1998), but data in relation to a multivariate analysis of risk factors in relation to Alzheimer’s disease in Down’s syndrome will be presented in this paper. The study was performed with the approval of the local research ethics committee and written, informed consent was obtained from participants or carers where appropriate.

Statistical analysis
The $\chi^2$ and Fisher’s exact tests were used to test for association between APOE and Alzheimer’s disease in Down’s syndrome. Multiple logistic regression analysis was also carried out to estimate the relative influence of risk factors such as age, gender, APOE and PS-1 genotype on the development of Alzheimer’s disease in adults with Down’s syndrome. A Mann–Whitney U-test was used to test for a relationship between APOE and the age of onset of Alzheimer’s disease in Down’s syndrome.

A probability of less than one in 20 ($P<0.05$) was regarded as significant in all statistical analyses.

RESULTS
Current study
The age range of the total cohort of adults with Down’s syndrome was between 35 and 72 years (mean 51, s.d.=7.8 years). Twenty-three (40.4%) were aged between 35 and 49 years, and 34 (59.6%) were 50 years or older. The age range of Down’s syndrome adults with dementia was between 35 and 71 (mean 34, s.d.=7.24), and those without dementia was between 35 and 72 years (mean 49, s.d.=7.55). Thirty-one (54.4%) were male and 26 (45.6%) were female. Thirteen (22.8%) had mild (IQ 70–50), 37 (63%) moderate (IQ 50–35), and seven severe (12.2%) intellectual disability (IQ<35). There was no statistically significant difference in the proportion of subjects with different degrees of severity of learning disability between the adults with dementia and the non-demented adults with Down’s syndrome.

The distribution of APOE alleles among the three study groups is shown in Table 1, while the distribution of APOE genotypes is presented in Table 2. No statistically significant differences were observed in any of the inter-group comparisons shown in Table 1 and Table 2. However, a higher frequency of $e4$ allele (17% $v.$ 9%; $\chi^2=1.4, P=0.2$) and a lower frequency of $e2$ allele (0% $v.$ 4.5%) ($P=0.26$: Fisher’s exact test) were observed among adults with Down’s syndrome with dementia compared with those without (see Table 1).

Adults with Down’s syndrome were divided up into two age groups (below 50 years, and 50 years and older), and two gender groups (male and female). This was done because of Sekijima et al.’s (1998) finding that the frequency of $e4$ allele in Down’s syndrome adults with Alzheimer’s disease under 50 years was significantly higher (28.6%), and Schupf et al.’s (1998) finding of earlier onset of Alzheimer’s disease in men with Down’s syndrome. The APOE $e4$ allele frequency between the adults with dementia and the non-demented adults with Down’s syndrome according to the age- and gender-groups are presented in Table 3. None of the inter-group comparisons in Table 3 was statistically significant.

A multiple logistic regression analysis was carried out in the whole cohort of adults with Down’s syndrome using the presence of dementia as a dependent variable and age, gender, APOE status, and PS-1 polymorphism as covariates. The presence of dementia was only significantly related to age in adults with Down’s syndrome.

To assess the influence of APOE $e4$ on the age of onset of dementia in adults with Down’s syndrome we compared the mean age of onset between those who had an $e4$ allele and those who did not. The mean age of onset of dementia among $e4$ positive cases (at least one $e4$ allele) was 51 years and 53 years for those who did not have an $e4$ allele. A comparison of ages of onset in those with and without an $e4$ allele was not statistically significant.

Meta-analysis
Prasher et al. (1997) presented a meta-analysis of the data collected from all the known published papers in addition to their own data in relation to APOE status in adults with Down’s syndrome with and without Alzheimer’s disease. We have added data from two other recent studies (Sekijima et al., 1998; Tyrell et al., 1998), and our current

\begin{table}[h]
\centering
\caption{APOE allele frequency in different groups}
\begin{tabular}{|l|c|c|c|}
\hline
 & $\epsilon2$, n (%) & $\epsilon3$, n (%) & $\epsilon4$, n (%) \\
\hline
Adults with dementia with Down’s syndrome (n=24) & 0 & 40 (83.0) & 8 (17.0) \\
Non-demented adults with Down’s syndrome (n=33) & 3 (4.5) & 57 (86.5) & 6 (9.0) \\
All adults with Down’s syndrome (n=57) & 3 (2.6) & 97 (85.0) & 14 (12.3) \\
Non-learning disabled control group (n=164) & 23 (7.0) & 264 (80.0) & 41 (13.0) \\
\hline
\end{tabular}
\end{table}

\begin{table}[h]
\centering
\caption{APOE genotypes in different groups}
\begin{tabular}{|l|c|c|c|c|c|c|c|}
\hline
 & $\epsilon4c4$, n (%) & $\epsilon4c2$, n (%) & $\epsilon4c3$, n (%) & $\epsilon3c3$, n (%) & $\epsilon3c2$, n (%) & $\epsilon2c2$, n (%) \\
\hline
Adults with dementia with Down’s syndrome (n=24) & 0 & 0 & 8 (33.3) & 16 (66.7) & 0 & 0 \\
Non-demented adults with Down’s syndrome (n=33) & 0 & 0 & 6 (18.2) & 24 (72.7) & 3 (9.1) & 0 \\
All adults with Down’s syndrome (n=57) & 0 & 0 & 14 (24.6) & 40 (70.2) & 3 (5.2) & 0 \\
Non-learning disabled control group (n=164) & 3 (1.8) & 3 (1.8) & 32 (19.5) & 108 (65.8) & 16 (9.7) & 2 (1.2) \\
\hline
\end{tabular}
\end{table}
study to those analysed by Prasher et al. (1997) and this is presented in Table 4. However, we excluded Wisniewski et al.'s (1995) data, which were included in Prasher et al.'s (1997) meta-analysis, because unlike all the other studies they diagnosed Alzheimer’s disease on the basis of neuropathological findings alone in the absence of any clinical data. The previous meta-analysis (Prasher et al., 1997) did not show a statistically significant difference in the distribution of APOE alleles between the adults with dementia and Down’s syndrome and the non-demented adults with Down’s syndrome. However, the meta-analysis in the current study showed a statistically significant excess of APOE ε4 in Down’s syndrome cases with Alzheimer’s disease compared with those without (odds ratio = 2.02, 95% CI 1.33–3.07, \( \chi^2 = 10.83, P = 0.001 \)) with no evidence of heterogeneity (P = 0.2). We did not observe a significantly lower rate of APOE ε2 allele frequency in Down’s syndrome adults with Alzheimer’s disease (odds ratio = 0.69, 95% CI 0.35–1.37). The odds ratios along with 95% CIs of those individual studies where a statistically significant excess of APOE ε4 or reduction of ε2 allele frequency was observed among adults with Down’s syndrome with Alzheimer’s disease are presented at the bottom of Table 4.

### DISCUSSION

#### The current study

We observed a higher frequency of the APOE ε4 allele among subjects with dementia and Down’s syndrome compared with those without dementia, although this trend was not statistically significant. Similarly a slightly lower frequency of the protective ε2 allele was observed among the adults with dementia and Down’s syndrome. The small cohort size of the current study reduced the statistical power for this study (24% power at 5% level) to detect an effect size of that reported previously. However, in this study the age-matching of two groups of patients with Down’s syndrome one of which had dementia, was done in such a way so as to increase its sensitivity and thus lessen the influence of this statistical weakness.

#### Meta-analysis

To increase the possibility of detecting small effect sizes, we collated data from all known published studies of association between APOE status in Down’s syndrome and Alzheimer’s disease. This was the method employed recently by Prasher et al. (1997) that showed no evidence to support an involvement of APOE. However, the meta-analysis reported here, showed a statistically significant excess of the APOE ε4 allele among the subjects with dementia when compared with the non-demented group of adults with Down’s syndrome. However, we did not observe a significant reduction of APOE ε2 alleles among the adults with dementia and Down’s syndrome.

### Table 3: Frequency of APOE ε4 and ε2 alleles in adults with Down’s syndrome according to age and gender group

<table>
<thead>
<tr>
<th></th>
<th>ε4 frequency</th>
<th></th>
<th>ε2 frequency</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Demented subjects, n (%)</td>
<td>Non-demented subjects, n (%)</td>
<td>Demented subjects, n (%)</td>
<td>Non-demented subjects, n (%)</td>
</tr>
<tr>
<td>Age &lt; 50 years (n = 23)</td>
<td>2 (25)</td>
<td>2 (33.3)</td>
<td>0</td>
<td>1 (33.3)</td>
</tr>
<tr>
<td>Age ≥ 50 years (n = 34)</td>
<td>6 (75)</td>
<td>4 (66.6)</td>
<td>0</td>
<td>2 (66.7)</td>
</tr>
<tr>
<td>Male (n = 31)</td>
<td>3 (37.5)</td>
<td>3 (50)</td>
<td>0</td>
<td>3 (100)</td>
</tr>
<tr>
<td>Female (n = 26)</td>
<td>5 (62.5)</td>
<td>3 (50)</td>
<td>0</td>
<td>0</td>
</tr>
</tbody>
</table>

### Table 4: Meta-analysis of pooled data from reports on APOE allele frequency in adults with and without dementia (updated from Prasher et al.’s (1997) data)

<table>
<thead>
<tr>
<th>Study</th>
<th>Adults with Down’s syndrome with dementia (allele frequency) n (%)</th>
<th>Adults with Down’s syndrome without dementia (allele frequency) n (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>ε2</td>
<td>ε3</td>
</tr>
<tr>
<td>Royston et al. (1994)</td>
<td>34</td>
<td>1 (3.0)</td>
</tr>
<tr>
<td>van Gool et al. (1995)</td>
<td>52</td>
<td>2 (3.8)</td>
</tr>
<tr>
<td>Martins et al. (1995)¹</td>
<td>12</td>
<td>1 (8.3)</td>
</tr>
<tr>
<td>Gambert et al. (1996)</td>
<td>16</td>
<td>1 (6.2)</td>
</tr>
<tr>
<td>Schupf et al. (1996)²</td>
<td>26</td>
<td>0</td>
</tr>
<tr>
<td>Prasher et al. (1997)</td>
<td>34</td>
<td>4 (11.8)</td>
</tr>
<tr>
<td>Tyrell et al. (1998)</td>
<td>62</td>
<td>0</td>
</tr>
<tr>
<td>Sekijima et al. (1998)²</td>
<td>32</td>
<td>2 (6.3)</td>
</tr>
<tr>
<td>Current study</td>
<td>48</td>
<td>0</td>
</tr>
<tr>
<td>Total group</td>
<td>316</td>
<td>12 (3.8)</td>
</tr>
</tbody>
</table>

ε4 v. rest: 1. Odds ratio = 16.50 (95% CI 1.62–168); 2. odds ratio = 3.16 (95% CI 1.19–8.39); 3. odds ratio = 3.12 (95% CI 1.08–9.03).

Meta-analysis: ε4 v. rest: odds ratio = 2.03 (95% CI 1.33–3.07), pooled \( \chi^2 = 10.83, P = 0.001 \).

Meta-analysis: ε2 v. rest: odds ratio = 0.69 (95% CI 0.35–1.37).
Certain factors may have influenced the outcome of the meta-analysis in the current study as well as in Prasher et al.'s (1997) study. It is likely that the age difference in the cohorts used in the previous studies (Table 4) is a factor that may have introduced errors into the results of meta-analysis. The age range of subjects included in these studies varied, in that some used age 18 whereas others used age 35, 40 and 50 respectively as the minimum age for inclusion in the study. If APOE is responsible for earlier age of onset of Alzheimer’s disease, this differential rate of age range among the different cohorts will make the interpretation of meta-analysis difficult. The lack of appropriately matched control group is another likely source of bias. Only the current study, Tyrell et al.’s (1998) study and van Gool et al.’s (1995) study matched the dementia group with the non-dementia group. Prasher et al.’s (1997) study while not originally matched demonstrated no statistically significant difference between the two groups in the age and the gender distribution. The cohort size is also a likely source of error. Apart from the current study, only two other studies (see Table 4) included 20 or more adults with dementia in their cohort. Another source of error is the use of different diagnostic criteria for defining dementia in different studies. Some used formal tools like the DMR scale (Evenhuis, 1992) and Adaptive Behaviour Scale (Nihira et al., 1974), whereas others made their diagnosis on the basis of clinical findings alone.

Age of onset of Alzheimer’s disease

In the current study, a regression analysis unequivocally showed an influence of age on the occurrence of Alzheimer’s disease in adults with Down’s syndrome. Age is a well-known risk factor for the development of Alzheimer’s disease in both the general population and in the adults with Down’s syndrome. This effect seems more pronounced among the adults with Down’s syndrome. Some have suggested that age of death among adults with Down’s syndrome is influenced by the APOE status. In Hardy et al.’s (1994) autopsy study, the Down’s syndrome cases showing Alzheimer’s disease neuropathology and who had an APOE ε4 (n=10) allele, tended to die at a younger age (age of death ranged between 48 and 60 years, mean 54, s.d. =6) than those who had an ε2 allele (n=2) (age of death 69 and 76 years respectively). A similar trend was also reported by both Royston et al. (1994) and Mann et al. (1995) based on their small cohort studies. Some suggested that APOE status also influences the age of onset of Alzheimer’s disease in the general population (Corder et al., 1993). However, the findings of the current study do not suggest such trend among cases of Down’s syndrome. Considering the small cohort size included for the analysis of age of onset data in the current study, a Type II error is likely to influence the outcome. As early symptoms of Alzheimer’s disease could be difficult to detect in adults with Down’s syndrome, it is difficult to be precise about the exact age of onset of Alzheimer’s disease in this cohort.

The frequency of APOE ε4 allele distribution among the adults with dementia and Down’s syndrome in different studies mentioned in Table 4 varied between 12.5% and 33.4%, apart from Prasher et al.’s (1997) study, which showed a much lower (5.9%) frequency than that expected in the general population. In contrast, the frequency of APOE ε2 alleles varied widely between 0% in the current study, and that of Schupf et al.’s (1996) and Tyrell et al.’s (1998), to the 11.8% observed in Prasher et al.’s (1997) study, which is higher than expected even for the general population. The frequency of ε2 allele among the nondemented subjects with Down’s syndrome was on average much higher than that expected in the general population, with a wide range between 2.3% in Sekijima et al.’s (1998) study and 50% in Royston et al.’s (1994) study. Overall these data are indicative of APOE ε4 being a risk factor for the manifestation of Alzheimer’s disease in adults with Down’s syndrome.

APOE ε4 and Alzheimer’s disease neuropathology in Down’s syndrome

The findings of autopsy studies of patients with Down’s syndrome, however, show a somewhat unclear relationship between APOE ε4 and Alzheimer’s disease neuropathology in this population. For example, in Wisniewski et al.’s (1995) autopsy study of brains of 40 subjects with Down’s syndrome (of whom 15 showed Alzheimer’s disease neuropathology), only one 21-year-old subject had an APOE ε4 allele (ε3ε4 genotype) and his brain did not show the Alzheimer’s disease neuropathology. In Mann et al.’s (1995) study of 20 brains of subjects with Down’s syndrome, all of whom showed Alzheimer’s disease neuropathology, only 35% (n=7) had APOE ε4 allele (one with ε2ε4 and six with ε3ε4). Similarly, in Hardy et al.’s (1994) series of 22 autopsy brains of subjects with Down’s syndrome, all of whom showed Alzheimer’s disease neuropathology, 45% (n=10) had APOE ε4 (all with ε3ε4 allele). Further research is needed to clarify this apparent discrepancy perhaps by using immunoneuropathological techniques. It is also important to explore the exact mechanism by which APOE ε4 may influence the clinical manifestation of Alzheimer’s disease in Down’s syndrome subjects. However, it is well known that despite the increased risk associated with the ε4 allele, the presence of ε4 is neither necessary nor sufficient for the development of Alzheimer’s disease (Blacker & Tanzi, 1998).

ACKNOWLEDGEMENTS

We thank all the subjects and their carers for taking part in the study, Dr Frank Dunstan for his advice on statistical analysis and Mrs J Wheeler for typing the manuscript.

REFERENCES


CLINICAL IMPLICATIONS

- APOE e4 allele influences the manifestation of Alzheimer’s disease in adults with Down’s syndrome.
- The role of APOE e2 allele in relation to Alzheimer’s disease in adults with Down’s syndrome is not clear.
- The influence of APOE e4 allele on the age of onset of Alzheimer’s disease in adults with Down’s syndrome is not clear.

LIMITATIONS

- The studies included in the meta-analysis used cohorts of different age groups.
- The adults with Down’s syndrome without Alzheimer’s disease were not always matched in these studies.
- Criteria used for diagnosing Alzheimer’s disease varied in different studies.

SHOUMITRO DEB, FRCPsych, JOHN BRAGANZA, MRCPsych, NADINE NORTON, BSc, HYWEL WILLIAMS, BSc, PATRICK G. KEHOE, PhD, JULIE WILLIAMS, PhD, MICHAEL OWEN, FRCPsych, Division of Psychological Medicine, University of Wales College of Medicine, Cardiff

Correspondence: Dr S. Deb, Division of Psychological Medicine, University of Wales College of Medicine, Heath Park, Cardiff CF4 4XN. Tel: 01222 562323. Fax: 0122 555047. E-mail: Deb@Cardiff.ac.uk

(First received 15 June 1999, final revision 29 September 1999, accepted 1 October 1999)
$APOE\ ?4$ influences the manifestation of Alzheimer's disease in adults with Down's syndrome

SHOUIMITRO DEB, JOHN BRAGANZA, NADINE NORTON, HYWEL WILLIAMS, PATRICK G. KEHOE, JULIE WILLIAMS and MICHAEL OWEN

Access the most recent version at DOI: 10.1192/bjp.176.5.468

References
This article cites 20 articles, 3 of which you can access for free at:
http://bjp.rcpsych.org/content/176/5/468#BIBL

Reprints/permissions
To obtain reprints or permission to reproduce material from this paper, please write to permissions@rcpsych.ac.uk

You can respond to this article at
/letters/submit/bjpncpsych;176/5/468

Downloaded from
http://bjp.rcpsych.org/ on October 6, 2016
Published by The Royal College of Psychiatrists